Journal of Clinical Oncology, Vol 12, 1343-1348, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma

A Lopez-Guillermo, E Montserrat, F Bosch, MJ Terol, E Campo and C Rozman
Postgraduate School of Hematology, Farreras Valenti, University of Barcelona, Spain.

PURPOSE: Variables used to build up the International Index for aggressive lymphomas (age, performance status, stage, extranodal involvement, and lactic dehydrogenase [LDH]) are also important in low- grade lymphoma. To assess the prognostic value of this index in low- grade lymphoma, we have applied it to a series of 125 patients. PATIENTS AND METHODS: One hundred twenty-five patients with low-grade lymphoma who were diagnosed at a single institution over a 20-year period and treated with standard chemotherapy were studied. End points of the study were response to therapy and survival according to the International Index. In addition to the International Index, main initial and evolutive variables were evaluated. Univariate and multivariate methods were used. RESULTS: After applying the International Index, the patients divided into four risk groups: low (36% of cases), low-intermediate (32%), high-intermediate (20.8%), and high (11.2%), with complete response (CR) rates in the four groups being 60%, 35%, 23%, and 21%, respectively. Ten-year overall survival rates for the risk groups were as follows: low, 73.6%; low- intermediate, 45.2%; high-intermediate, 53.5%; and high, 0% (P < .001). When the International Index was included in a multivariate analysis, along with the main initial variables, International Index (P < .001) and sex (male, worse) (P = .038) were the only parameters related to survival. When response to therapy was also included, achievement of CR (P < .0001) and International Index (P < .001) were the most important factors. In patients who achieved a CR, the International Index was the only parameter related to survival (P = .051). The results were the same when the International Index was applied to the subset of 107 patients with follicular lymphoma. CONCLUSION: In this study, the International Index has been found to be an important prognostic tool in low-grade lymphomas. Such an index could be used to predict prognosis not only in aggressive, but also in low-grade lymphomas.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma Blood, June 4, 2009; 113(23): 5743 - 5746. [Abstract] [Full Text] [PDF]

				S. Park, J. Lee, Y. H. Ko, A. Han, H. J. Jun, S. C. Lee, I. G. Hwang, Y. H. Park, J. S. Ahn, C. W. Jung, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma Blood, August 1, 2007; 110(3): 972 - 978. [Abstract] [Full Text] [PDF]

				A. Koster, H. A. Tromp, J. M.M. Raemaekers, G. F. Borm, K. Hebeda, M. A. MacKenzie, and J. H.J.M. van Krieken The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma Haematologica, February 1, 2007; 92(2): 184 - 190. [Abstract] [Full Text] [PDF]

				L. Arcaini, M. Lazzarino, N. Colombo, S. Burcheri, E. Boveri, M. Paulli, E. Morra, M. Gambacorta, S. Cortelazzo, A. Tucci, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use Blood, June 15, 2006; 107(12): 4643 - 4649. [Abstract] [Full Text] [PDF]

				G. Perea, A. Altes, S. Montoto, A. Lopez-Guillermo, E. Domingo-Domenech, A. Fernandez-Sevilla, J. M. Ribera, J. Grau, C. Pedro, J. Angel Hernandez, et al. Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems Ann. Onc., September 1, 2005; 16(9): 1508 - 1513. [Abstract] [Full Text] [PDF]

				M. J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke, and E. Moser Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET? Ann. Onc., September 1, 2005; 16(9): 1524 - 1529. [Abstract] [Full Text] [PDF]

				S. S. Dave, G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells N. Engl. J. Med., November 18, 2004; 351(21): 2159 - 2169. [Abstract] [Full Text] [PDF]

				P. Solal-Celigny, P. Roy, P. Colombat, J. White, J. O. Armitage, R. Arranz-Saez, W. Y. Au, M. Bellei, P. Brice, D. Caballero, et al. Follicular Lymphoma International Prognostic Index Blood, September 1, 2004; 104(5): 1258 - 1265. [Abstract] [Full Text] [PDF]

				P. Corradini, M. Ladetto, F. Zallio, M. Astolfi, E. Rizzo, S. Sametti, A. Cuttica, R. Rosato, L. Farina, M. Boccadoro, et al. Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes J. Clin. Oncol., April 15, 2004; 22(8): 1460 - 1468. [Abstract] [Full Text] [PDF]

				J. F. Seymour, B. Pro, L. M. Fuller, J. T. Manning, F. B. Hagemeister, J. Romaguera, M. A. Rodriguez, C. S. Ha, T. L. Smith, A. Ayala, et al. Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I-II Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., June 1, 2003; 21(11): 2115 - 2122. [Abstract] [Full Text] [PDF]

				W. S. Velasquez, D. Lew, T. M. Grogan, C. H. Spiridonidis, S. P. Balcerzak, S. R. Dakhil, T. P. Miller, K. S. Lanier, R. A. Chapman, and R. I. Fisher Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501 J. Clin. Oncol., May 15, 2003; 21(10): 1996 - 2003. [Abstract] [Full Text] [PDF]

				A. Viardot, P. Moller, J. Hogel, K. Werner, G. Mechtersheimer, A. D. Ho, G. Ott, T. F.E. Barth, R. Siebert, S. Gesk, et al. Clinicopathologic Correlations of Genomic Gains and Losses in Follicular Lymphoma J. Clin. Oncol., December 1, 2002; 20(23): 4523 - 4530. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, S. Litchy, H. A. Burris III, D. C. Scullin Jr, S. W. Corso, D. A. Yardley, L. Morrissey, and F. A. Greco Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin's Lymphoma J. Clin. Oncol., October 15, 2002; 20(20): 4261 - 4267. [Abstract] [Full Text] [PDF]

				M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) Blood, August 13, 2002; 100(5): 1559 - 1565. [Abstract] [Full Text] [PDF]

				T. Igarashi, Y. Kobayashi, M. Ogura, T. Kinoshita, T. Ohtsu, Y. Sasaki, Y. Morishima, T. Murate, M. Kasai, N. Uike, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study Ann. Onc., June 1, 2002; 13(6): 928 - 943. [Abstract] [Full Text] [PDF]

				P. McLaughlin Profiling: "Editorial on 'Survival after progression in patients with follicular lymphoma: analysis of prognostic factors' ", by S. Montoto et al. (Ann Oncol 2002; 13: 523-530) Ann. Onc., April 1, 2002; 13(4): 499 - 500. [Full Text] [PDF]

				S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors Ann. Onc., April 1, 2002; 13(4): 523 - 530. [Abstract] [Full Text] [PDF]

				T. A. Davis, A. J. Grillo-Lopez, C. A. White, P. McLaughlin, M. S. Czuczman, B. K. Link, D. G. Maloney, R. L. Weaver, J. Rosenberg, and R. Levy Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment J. Clin. Oncol., September 17, 2000; 18(17): 3135 - 3143. [Abstract] [Full Text] [PDF]

				R. I. Fisher, B. W. Dana, M. LeBlanc, C. Kjeldsberg, J. D. Forman, J. M. Unger, S. P. Balcerzak, E. R. Gaynor, V. Roy, and T. Miller Interferon Alfa Consolidation After Intensive Chemotherapy Does Not Prolong the Progression-Free Survival of Patients With Low-Grade Non-Hodgkin's Lymphoma: Results of the Southwest Oncology Group Randomized Phase III Study 8809 J. Clin. Oncol., May 10, 2000; 18(10): 2010 - 2016. [Abstract] [Full Text] [PDF]

				T. L. Pandolfino, R. S. Siegel, T. M. Kuzel, S. T. Rosen, and J. Guitart Primary Cutaneous B-Cell Lymphoma: Review and Current Concepts J. Clin. Oncol., May 10, 2000; 18(10): 2152 - 2168. [Abstract] [Full Text] [PDF]

				M. E. Kadin Regulation of CD30 Antigen Expression and Its Potential Significance for Human Disease Am. J. Pathol., May 1, 2000; 156(5): 1479 - 1484. [Full Text] [PDF]

				M. Federico, U. Vitolo, P. L. Zinzani, T. Chisesi, V. Clo, G. Bellesi, M. Magagnoli, M. Liberati, C. Boccomini, P. Niscola, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases Blood, February 1, 2000; 95(3): 783 - 789. [Abstract] [Full Text] [PDF]

				D. Decaudin, E. Lepage, N. Brousse, P. Brice, J.-L. Harousseau, K. Belhadj, H. Tilly, L. Michaux, S. Cheze, B. Coiffier, et al. Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients--A Study of the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., August 1, 1999; 17(8): 2499 - 2499. [Abstract] [Full Text] [PDF]

				T. A. Davis, C. A. White, A. J. Grillo-Lopez, W. S. Velasquez, B. Link, D. G. Maloney, R. O. Dillman, M. E. Williams, A. Mohrbacher, R. Weaver, et al. Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab J. Clin. Oncol., June 1, 1999; 17(6): 1851 - 1851. [Abstract] [Full Text] [PDF]

				F. Grange, G. Hedelin, P. Joly, M. Beylot-Barry, M. D'Incan, M. Delaunay, L. Vaillant, M.F. Avril, J. Bosq, J. Wechsler, et al. Prognostic Factors in Primary Cutaneous Lymphomas Other Than Mycosis Fungoides and the Sezary Syndrome Blood, June 1, 1999; 93(11): 3637 - 3642. [Abstract] [Full Text] [PDF]

				M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma Clin. Cancer Res., May 1, 1999; 5(5): 1085 - 1091. [Abstract] [Full Text] [PDF]

				A. Lopez-Guillermo, F. Cabanillas, T. I. McDonnell, P. McLaughlin, T. Smith, W. Pugh, F. Hagemeister, M. A. Rodriguez, J. E. Romaguera, A. Younes, et al. Correlation of Bcl-2 Rearrangement With Clinical Characteristics and Outcome in Indolent Follicular Lymphoma Blood, May 1, 1999; 93(9): 3081 - 3087. [Abstract] [Full Text] [PDF]

				C. Nicolaides, S. Dimou, and N. Pavlidis Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas Oncologist, June 1, 1998; 3(3): 189 - 197. [Abstract] [Full Text]

				R. Ristamaki, H. Joensuu, K. Lappalainen, L. Teerenhovi, and S. Jalkanen Elevated Serum CD44 Level Is Associated With Unfavorable Outcome in Non-Hodgkin's Lymphoma Blood, November 15, 1997; 90(10): 4039 - 4045. [Abstract] [Full Text] [PDF]

				D. G. Maloney, A. J. Grillo-Lopez, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T.-M. Liles, B. K. Dallaire, et al. IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Blood, September 15, 1997; 90(6): 2188 - 2195. [Abstract] [Full Text] [PDF]